摘要
目的：观察重症监护病房下呼吸道感染患者的用药及治疗情况，分析注射用头孢哌酮/舒巴坦的疗效及安全性，为临床资料提供参考依据。方法收集2012年3月-2013年5月共63例下呼吸道感染患者，随机分为A组31例和B组32例；A组在对症治疗的基础上给予头孢哌酮治疗，B组以头孢哌酮/舒巴坦为主进行治疗，比较两组的临床有效率和病原菌清除率，对比其不良反应的发生率，数据采用SPSS15．0软件进行分析。结果 A组的临床有效率为64．5％，病原菌清除率为74．6％，临床不良反应发生率为19．4％，与之相比，B组的有效率为75．1％，病原菌清除率为93．1％，不良反应发生率为9．3％，差异有统计学意义（ P＜0．05）。结论注射用头孢哌酮/舒巴坦治疗重症监护病房下呼吸道感染患者能提高疗效，降低不良反应的发生率，具有广泛的有效性和安全性。
Abstract
OBJECTIVE To analyze the efficacy and safety of cefoperazone/sulbactam by observation of medication and treatment for patients with lower respiratory tract infections in ICU .METHODS Totally 63 patients with low-er respiratory tract infections during Mar .2010 to May 2013 were randomly divided into the cefoperazone group (group A ,n=31) and the cefoperazone/sulbactam group (group B ,n=32) .Group A received cefoperazone in addition to the symptomatic treatment ,while group B used cefoperazone/sulbactam as the primary treatment .The two groups were compared for the clinical efficiency and pathogen clearance rate ,as well as the adverse reactions . Data were analyzed by SPSS 15 .0 software .RESULTS The clinical effective rate of group A was 64 .5% ,the pathogen clearance rate was 74 .6% ,the incidence of clinical adverse events was 19 .4% .In contrast ,the effective rate in group B was 75 .1% ,the pathogen clearance rate was 93 .1% ,the clinical adverse events was 9 .3% ,the difference was significant(P<0 .05) .CONCLUSION Cefoperazone/sulbactam for injection can improve efficacy of lower respiratory tract infections ,reduce the occurrence of adverse events in ICU ,which has broad efficacy and safety .
基金项目
山东省莱芜市科技局基金资助项目(YYLX2012019)
NETL
NSTL
维普
万方数据